FloBio, a medical diagnostics company, announced it received FDA Breakthrough Device Designation for a bleeding risk diagnostic test on October 17, 2023.
FloBio received FDA Breakthrough Device Designation for a bleeding risk diagnostic test in October 2023. The page also lists data presented at ISTH in June 2023.
FloBio LLC, formed in August 2017 as a spin-out of the University of Pennsylvania (UOP), is developing a fluidic-based diagnostic platform to assess bleeding and thrombotic risk at the point of care.
FloBio LLC lists its mailing address as 3401 Grays Ferry Avenue, Building 450, Philadelphia, PA 19146, and its email as admin@flobiollc.com. The page also links to LinkedIn.
FloBio says rapid diagnosis of bleeding and clotting risk and restoration of hemostasis can be critical in emergency, trauma, and critical care settings. FloBio was a 2022 semi-finalist in the AACC Disruptive Technology Competition and planned to attend AACC July 24–28 in Chicago.